GMAB
Price
$21.41
Change
-$0.35 (-1.61%)
Updated
Jun 3, 04:22 PM (EDT)
Capitalization
12.96B
65 days until earnings call
LSTA
Price
$2.67
Change
-$0.08 (-2.92%)
Updated
Jun 3, 04:26 PM (EDT)
Capitalization
23.56M
76 days until earnings call
Interact to see
Advertisement

GMAB vs LSTA

Header iconGMAB vs LSTA Comparison
Open Charts GMAB vs LSTABanner chart's image
Genmab A/S ADS
Price$21.41
Change-$0.35 (-1.61%)
Volume$660
Capitalization12.96B
Lisata Therapeutics
Price$2.67
Change-$0.08 (-2.92%)
Volume$100
Capitalization23.56M
GMAB vs LSTA Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. LSTA commentary
Jun 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a StrongBuy and LSTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2025
Stock price -- (GMAB: $21.77 vs. LSTA: $2.74)
Brand notoriety: GMAB and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 130% vs. LSTA: 35%
Market capitalization -- GMAB: $12.96B vs. LSTA: $23.56M
GMAB [@Biotechnology] is valued at $12.96B. LSTA’s [@Biotechnology] market capitalization is $23.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, LSTA is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 7 TA indicator(s) are bullish while LSTA’s TA Score has 6 bullish TA indicator(s).

  • GMAB’s TA Score: 7 bullish, 3 bearish.
  • LSTA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than LSTA.

Price Growth

GMAB (@Biotechnology) experienced а +4.61% price change this week, while LSTA (@Biotechnology) price change was +1.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.43%. For the same industry, the average monthly price growth was +5.48%, and the average quarterly price growth was +2.00%.

Reported Earning Dates

GMAB is expected to report earnings on Aug 07, 2025.

LSTA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+8.43% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($13B) has a higher market cap than LSTA($23.6M). GMAB YTD gains are higher at: 4.312 vs. LSTA (-8.054). GMAB has higher annual earnings (EBITDA): 9.7B vs. LSTA (-22.24M). GMAB has more cash in the bank: 3.23B vs. LSTA (31.2M). LSTA has less debt than GMAB: LSTA (137K) vs GMAB (143M). GMAB has higher revenues than LSTA: GMAB (21.6B) vs LSTA (1M).
GMABLSTAGMAB / LSTA
Capitalization13B23.6M55,085%
EBITDA9.7B-22.24M-43,607%
Gain YTD4.312-8.054-54%
P/E Ratio12.29N/A-
Revenue21.6B1M2,160,000%
Total Cash3.23B31.2M10,340%
Total Debt143M137K104,380%
FUNDAMENTALS RATINGS
GMAB vs LSTA: Fundamental Ratings
GMAB
LSTA
OUTLOOK RATING
1..100
877
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7550
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (25) in the null industry is somewhat better than the same rating for GMAB (60). This means that LSTA’s stock grew somewhat faster than GMAB’s over the last 12 months.

LSTA's Profit vs Risk Rating (100) in the null industry is in the same range as GMAB (100). This means that LSTA’s stock grew similarly to GMAB’s over the last 12 months.

LSTA's SMR Rating (100) in the null industry is in the same range as GMAB (100). This means that LSTA’s stock grew similarly to GMAB’s over the last 12 months.

LSTA's Price Growth Rating (50) in the null industry is in the same range as GMAB (75). This means that LSTA’s stock grew similarly to GMAB’s over the last 12 months.

LSTA's P/E Growth Rating (100) in the null industry is in the same range as GMAB (100). This means that LSTA’s stock grew similarly to GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABLSTA
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
62%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 21 days ago
69%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDWD22.240.28
+1.28%
MediWound Ltd
WAI1.86N/A
N/A
Top KingWin Ltd
EIX55.43-0.22
-0.40%
Edison International
DFH20.66-0.20
-0.96%
Dream Finders Homes
PRAA14.05-0.14
-0.99%
PRA Group

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+3.91%
GNMSF - GMAB
58%
Loosely correlated
N/A
AXON - GMAB
47%
Loosely correlated
+1.09%
ARGX - GMAB
38%
Loosely correlated
+1.98%
TECH - GMAB
37%
Loosely correlated
+0.43%
XENE - GMAB
37%
Loosely correlated
+4.23%
More

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+4.97%
RAIN - LSTA
29%
Poorly correlated
-15.26%
IMVT - LSTA
26%
Poorly correlated
+3.77%
ASND - LSTA
26%
Poorly correlated
+7.89%
MRUS - LSTA
25%
Poorly correlated
+4.39%
NAGE - LSTA
25%
Poorly correlated
+8.41%
More